If you have been exploring treatment options for depression that has not responded to antidepressants, you may have come across SPRAVATO® (esketamine). One of the first questions many patients ask is whether you need to be supervised after taking SPRAVATO®. The short answer is yes — and that requirement is not incidental. It is built into how the treatment is designed, administered, and monitored at our office.
SPRAVATO® is a nasal spray that you self-administer under direct clinical supervision. Because it can produce temporary side effects such as dissociation, dizziness, and elevated blood pressure, patients are observed by a medical professional throughout the entire session. Our psychiatrists are trained to support you through the experience, monitor how you respond, and document your progress after each visit.
After you take SPRAVATO®, you are required to stay at our office for at least two hours. During that time, your blood pressure will be checked at regular intervals, and a staff member will remain available to you throughout the observation window following SPRAVATO® administration. This is not a formality; it is a core part of the FDA-cleared treatment protocol and exists to ensure your safety.
The side effects that SPRAVATO® can produce are typically temporary and tend to resolve before the monitoring period ends. Most patients find that they are able to leave feeling close to their baseline once the two hours have passed. You will not be permitted to drive yourself home after each session, so arranging a ride in advance is an important part of your preparation for each appointment.
For some patients, the in-office SPRAVATO® supervision requirement raises practical questions around scheduling and time commitment. SPRAVATO® treatment involves twice-weekly sessions during the initial induction phase, which means building the monitoring time into your routine on a consistent basis. Our team works with adult and adolescent patients to find appointment windows that fit their schedules and to make each visit as manageable as possible.
The supervision protocol also serves a clinical purpose beyond immediate safety. The observations made during your post-dose monitoring period give our psychiatrists meaningful information about how you are responding to the esketamine nasal spray treatment. That data informs how your care is adjusted over time and supports a more individualized approach to your overall treatment plan.
Not every patient is a candidate for SPRAVATO®, and the supervision requirement is one of several factors worth discussing during an evaluation. Patients who have tried multiple antidepressants without adequate relief are often the strongest candidates, but a thorough psychiatric assessment is the right starting point.
Our team is experienced in determining whether this esketamine-monitored treatment aligns with your history, your goals, and the realities of your daily life.
If you are ready to learn more, reaching out for a consultation is the next step. We will walk you through what to expect during sessions, answer your questions about the monitoring protocol, and help you determine whether you need to be supervised after taking SPRAVATO® and whether this level of structured care is the right fit for you.
